Evidence map›Paper›PMID 40161254›Full record

ArticleOptica2022

Velocity-based optoretinography for clinical applications.

Kari V Vienola, Denise Valente, Robert J Zawadzki, Ravi S Jonnal

Abstract read
In one paragraph

Article in Optica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Article
  2. Article
  3. Subretinal Aspects of the Optoretinographic Response.Investigative ophthalmology & visual science · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. ƒ(Cell): Software for Reproducible Analysis of Optoretinograms.Translational vision science & technology · 2026
    Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Subretinal aspects of the optoretinographic response.bioRxiv : the preprint server for biology · 2025
    Article
  15. Article
  16. Article
  17. Review
  18. Frontiers in ophthalmology · 2025
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kari V VienolaVision Science and Advanced Retinal Imaging Laboratory, Department of Ophthalmology and Vision Science, University of California, Davis, Sacramento, California 95817, USA.ORCID 0000-0003-3390-392X
Denise ValenteVision Science and Advanced Retinal Imaging Laboratory, Department of Ophthalmology and Vision Science, University of California, Davis, Sacramento, California 95817, USA.ORCID 0000-0002-1377-3585
Robert J ZawadzkiVision Science and Advanced Retinal Imaging Laboratory, Department of Ophthalmology and Vision Science, University of California, Davis, Sacramento, California 95817, USA.ORCID 0000-0002-9574-156X
Ravi S JonnalVision Science and Advanced Retinal Imaging Laboratory, Department of Ophthalmology and Vision Science, University of California, Davis, Sacramento, California 95817, USA.ORCID 0000-0002-9545-1837

Funding

VISION RESEARCH CORE GRANTP30EY012576 · NEI · UNIVERSITY OF CALIFORNIA DAVIS · PI LISA M OAKES · 1999 to 2026
$18.9M
Theranostics of Photoreceptor-RPE-Choroid Neurovascular Unit in Mouse Models of Eye DiseasesR01EY026556 · NEI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Robert J Zawadzki · 2017 to 2026
$4.1M
The Phase I/II Randomized, Prospective, Double-blinded, Sham-controlled Cross-over Study of Intravitreal Autologous Bone Marrow CD34+ Stem Cell Therapy for Retinal Vein OcclusionUG1EY026876 · NEI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PARK, SUSANNA S · 2018 to 2022
$2.6M
Full Field OCT for Cellular Level Structural and Functional Retinal ImagingR01EY031098 · NEI · OHIO STATE UNIVERSITY · PI DOBLE, NATHAN, ZAWADZKI, ROBERT J · 2020 to 2023
$2.3M
OCT-based functional biomarkers for degenerative diseases of the photoreceptor-RPE-choroid neurovascular unitR01EY034340 · NEI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Ravi S. Jonnal, Robert J Zawadzki · 2023 to 2026
$2.2M
Investigating fundamental properties and clinical applications of the optoretinogramR01EY033532 · NEI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Ravi S. Jonnal · 2022 to 2026
$2.0M
Properties of Photoreceptors and Muller Cells Investigated with AO-OCTR00EY026068 · NEI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI JONNAL, RAVI S. · 2018 to 2020
$739k
NEI NIH HHS P30 EY012576NEI NIH HHS R00 EY026068NEI NIH HHS R01 EY026556NEI NIH HHS R01 EY031098NEI NIH HHS R01 EY033532NEI NIH HHS R01 EY034340NEI NIH HHS UG1 EY026876
6 · The paper itself

Abstract

Optoretinography (ORG) is an emerging tool for testing neural function in the retina. Unlike existing methods, it is noninvasive and objective, and provides information about retinal structure and function at once. As such, it has great potential to transform ophthalmic care and clinical trials of novel therapeutics designed to restore or preserve visual function. Recent efforts have demonstrated the feasibility of ORG using state-of-the-art optical coherence tomography systems. These methods measure the stimulus-evoked movement of subcellular features in the retina, using the phase of reflected light to monitor their positions. Here we present an alternative approach that monitors the velocity of these features instead. This conceptual shift has significant implications for the nascent field of ORG. By avoiding the need to track specific cells over time, it obviates costly and laborious aspects of position-based approaches, such as adaptive optics, digital aberration correction, real-time tracking, and three-dimensional segmentation and registration. We used this velocity-based approach to measure the photoreceptor ORG responses in three healthy subjects. The resulting responses were reproducible and exhibited dependence on dose and retinal eccentricity. The possibility of reconstructing the position signal through numerical integration of velocity was explored.

Identifiers

PMID40161254
PMCPMC11951274

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.